In vivo gene delivery to articular chondrocytes mediated by an adeno-associated virus vector
✍ Scribed by M Ulrich-Vinther; M.R Duch; K Søballe; R.J O’Keefe; E.M Schwarz; F.S Pedersen
- Publisher
- Elsevier Science
- Year
- 2004
- Tongue
- English
- Weight
- 917 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0736-0266
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Purposes. (1) To investigate the efficiency of direct in vivo adeno‐associated virus (AAV) vector‐mediated gene transduction to chondrocytes in relation to normal and injured articular cartilage. (2) To evaluate the effects of ultra‐violet light‐activated gene transduction (LAGT) in chondrocytes in vivo. (3) To determine dissemination of active rAAV vector after intra‐articular administration.
Methods. Rabbit knees with either normal or injured cartilage received an intra‐articular injection with 1.5 × 10^12^ infectious rAAV‐eGFP particles. The right knees received rAAV‐eGFP alone, whereas the left knees were given LAGT‐treatment. The transduction efficiencies were determined at 1 and 3 weeks after infection by fluorescence‐activated cell scanning. The occurrence of active shedding was monitored in serum and various tissues.
Results. After 1 week, 7% of the chondrocytes in normal cartilage were transduced by direct rAAV transduction technique. Chondrocytes in cartilage defects demonstrated higher transduction rates compared to chondrocytes in normal cartilage. LAGT increased the cellular eGFP expression in the internal zones to 12%, but did not have any effect in the external zones in defects. Finally, infectious particles were not detected in either serum or tissue samples.
Conclusions. Direct rAAV‐mediated gene transfer in vivo to articular chondrocytes is possible. LAGT improves rAAV transduction of chondrocytes in vivo but appears to have a very limited range of effect induction. Expression of eGFP was not determined in other tissues than synovium and cartilage in the treated joints. © 2003 Orthopaedic Research Society. Published by Elsevier Ltd. All rights reserved.
📜 SIMILAR VOLUMES
## Abstract ## Background The adeno‐associated virus (AAV) has many safety features that favor its use in the treatment of arthritic conditions; however, the conventional, single‐stranded vector is inefficient for gene delivery to fibroblastic cells that primarily populate articular tissues. This
## Abstract ## Objective To examine the effects of basic fibroblast growth factor (bFGF) gene–transduced chondrocytes on the repair of articular cartilage defects. ## Methods LacZ gene or bFGF gene was transduced into primary isolated rabbit chondrocytes with the use of a recombinant adeno‐assoc
## Abstract ## Background Vascular gene therapy requires safe and efficient gene transfer __in vivo__. Recombinant adeno‐associated virus (AAV) is a promising viral vector but its use in the vasculature has produced conflicting results and serotypes other than AAV2 have not been intensively studie
## Abstract ## Background Genetically modified chondrocytes may be able to modulate articular cartilage repair. To date, transplantation of modified chondrocytes into cartilage defects has been restricted to viral vectors. We tested the hypothesis that a recombinant gene can be delivered to sites
## Abstract ## Background The success of gene therapy for inherited neurodegenerative diseases such as metachromatic leukodystrophy (MLD) depends on the development of efficient gene delivery throughout the brain guarded by the blood–brain barrier and achieves distribution of the deficient enzyme